Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

BiomX Inc. (PHGE-UN)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
0.5941-0.0354 (-5.63%)
At close: 10:06AM EDT
Advertisement

BiomX Inc.

22 Einstein Street
Floor 5
Ness Ziona 7414003
Israel
972 7 2394 2377
https://www.biomx.com

Sector(s)
Industry
Full Time Employees103

Key Executives

NameTitlePayExercisedYear Born
Mr. Jonathan Eitan Solomon MBACEO & Director681.03kN/A1977
Mr. Assaf OronChief Bus. Officer352.04kN/A1974
Dr. Merav Bassan Ph.D.Chief Devel. Officer449.07kN/A1966
Prof. Rotem Sorek Ph.D.Scientific FounderN/AN/AN/A
Dr. Eran Elinav M.D., Ph.D.Scientific FounderN/AN/AN/A
Dr. Timothy K. Lu M.D., Ph.D.Scientific FounderN/AN/A1981
Ms. Marina Wolfson CPACFO & Sec.N/AN/A1984
Ms. Inbal Benjamini-ElranVP of HRN/AN/AN/A
Dr. Inbar Gahali-SassVP of Platform R&DN/AN/AN/A
Dr. Regis A. Vilchez M.D., Ph.D.Sr. VP & Head of Clinical Devel.N/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

Corporate Governance

BiomX Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement